China’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment of several immunological diseases.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
